The need for effective candidates
as cytotoxic drugs that at the
same time challenge cancer multidrug resistance encouraged a search
for these in plants of central Argentina. Bioassay-guided fractionation
of the cytotoxic extract from Dimerostemma aspilioides led to the isolation of the germacranolide tomenphantin A (1), along with three new analogues (2–4). These efficiently inhibited the proliferation of the leukemia
cell lines K562 and CCRF-CEM and their resistant variants, Lucena
1 and CEM/ADR5000, respectively, with IC50 values ranging
from 0.40 to 7.7 μM. The structures and relative configurations
of compounds 1–4 were elucidated
by analysis of the spectroscopic data, in particular NMR spectroscopy.
The most active among these was compound 1 (IC50 = 0.40–5.1 μM), and, therefore, this was selected as
a model for a mechanistic study, which revealed that its antiproliferative
effect was mediated by cell cycle arrest in the G2/M phase
followed by apoptosis. The activity of compound 1 was
selective, given the absence of cytotoxicity toward peripheral blood
mononuclear cells. The results show the potential of these compounds,
and in particular of compound 1, as leads for the development
of drug candidates to fight sensitive and resistant leukemia cells.